A breakthrough tool called Helicase-Assisted Continuous Editing (HACE) allows scientists to create precise genetic mutations in specific genes without affecting the rest of the genome. By combining helicase enzymes with CRISPR technology, HACE introduces mutations into targeted DNA sequences, advancing our ability to study gene functions and disease mechanisms. The tool has already identified drug resistance mutations in cancer-related genes and splicing defects in blood cancers, showcasing its potential for therapeutic discovery.
